Outcomes of Radiotherapy for Brain Metastases Patients without Active Extracranial Disease

Abstract

27% and 20%, respectively (pZ0.014). GKI-Spr also reduced the normal brain Dmean, V30 and V2 by 20%, 8% and 30%, respectively (pZ0.014). Conclusion: GKI yields superior hippocampal and normal brain dosimetry compared to HA-WBRT, and the novel GKI-Spr strategy may provide further dosimetric advantages compared with traditional GKI-Sfr.